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Abstract 
 
 
Dendritic cells are the main antigen processing and presenting cells in the body. One 
subset of dendritic cells is the Langerhans cells (LCs), which are localized in the 
epidermis. Under steady-state conditions they continuously migrate to skin-draining 
lymph nodes and present antigen to naïve T cells. Under inflammatory conditions, LC 
migration is enhanced and their cytokine release is increased, activating and 
recruiting other types of immune cells to the site of inflammation. It has been shown 
in our lab that Imiquimod, a Toll-like receptor (TLR)7 agonist, activates LC and can 
lead to the regression of skin tumours like melanoma. In human therapy it is 
successfully used in treatment of basal-cell carcinoma (BCC). However, the role of 
LC in mediation of the antitumor effect of Imiquimod is poorly understood. In my 
thesis I addressed the question, if the presence of LCs has any impact on skin 
tumour growth and if they are important mediators of the antitumor effect of 
Imiquimod. 
To address this question I employed two different mouse skin cancer models: (1) a 
syngeneic melanoma model, whereby B16F10 melanoma cells are injected 
intradermally into LangerinDTR:EGFP mice; and (2) mice carrying the 
SmoothenedM2 transgene (Rosa26SmoM2YFP mice) that can be induced to 
develop BCC.  
(1) LCs were not responsible for the antitumoral effect of Imiquimod in the 
B16F10 melanoma model. Tumour bearing mice treated with Imiquimod 
showed decreased tumour growth rates compared to untreated control mice. 
This result was obtained independent of presence of LCs. Analysis of the 
cellular composition of tumour infiltrates revealed a role of LCs in recruiting 
CD8+ T cells and MHCII+CD4+ cells to Imiquimod-treated tumours as well as a 
regulatory role on mast cell degranulation.  
(2) Rosa26SmoM2YFP mice were crossed to K5CreERT and LangerinDTR:EGFP 
mice to give rise to inducible BCC bearing mice which can be depleted of LCs 
(SmoM2LangerinDTR mice). Imiquimod application onto BCC for 2 weeks did 
not have any influence on tumour growth. Therefore experiments using 
extended treatment regimens are planned.  
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Zusammenfassung 
 
 
Dendritische Zellen sind die wichtigsten antigenprozessierenden und –
präsentierenden Zellen des Körpers. Die Langerhanszellen stellen eine 
Subpopulationen von dendritischen Zellen dar. Sie sind in der Epidermis lokalisiert 
und nehmen unter physiologischen Bedingungen beständig Antigen auf, migrieren zu 
hautdränierenden Lymphknoten und präsentieren Antigen an naive T Zellen. 
Während Entzündungsprozessen wird die Langerhanszell-Migration erhöht, ebenso 
ihre Freisetzung von Zytokinen. Dadurch werden andere Immunzell-Populationen 
aktiviert und zur Entzündungsstelle rekrutiert. Eine Studie in unserem Labor konnte 
zeigen, dass Imiquimod, ein Toll-like Rezeptor (TLR)7 Agonist, Langerhanszellen 
aktiviert und darüber hinaus zur Regression von Hauttumoren, wie z.B. Melanomen, 
führt. In humaner Therapie wird Imiquimod häufig in der erfolgreichen Behandlung 
von Basaliomen eingesetzt. Dennoch ist bisher nicht bekannt, welchen Beitrag die 
Langerhanszellen zur Wirkweise des antitumoralen Effekts von Imiquimod leisten. In 
meiner Diplomarbeit habe ich die Fragestellung bearbeitet, ob die Präsenz von 
Langerhanszellen einen Einfluss auf das Wachstum von Hautkrebs hat und ob sie 
wichtige Übermittler des antitumoralen Effekts von Imiquimod darstellen.  
 
Aus diesem Grund habe ich für die Studie zwei verschiedene Mausmodelle für 
Hautkrebs verwendet: (1) ein syngenes Melanom-Modell, wobei B16F10 
Melanomzellen intradermal in LangerinDTR:EGFP Mäuse injiziert werden; und (2) 
Mäuse, bei welchen das Wachstum von Basaliomen durch Expression eines 
hyperaktiven Smoothened-Allels induziert werden kann (Rosa26SmoM2YFP Mäuse).  
 
(1) Langerhanszellen sind nicht für den antitumoralen Effekt von Imiquimod im 
B16F10 Melanom-Modell verantwortlich. Tumore, die mit Imiquimod behandelt 
werden, weisen langsamere Tumorwachstumsraten auf als unbehandelte 
Tumore. Dieses Resultat kann unabhängig von der Präsenz von 
Langerhanszellen beobachtet werden. Die Analyse der zellulären 
Zusammensetzung von Tumorinfiltraten zeigt, dass Langerhanszellen eine 
Rolle in der Rekrutierung von CD8+ T Zellen und MHCII+CD4+ Zellen in 
Imiquimod-behandlete Tumore spielen. Ebenso scheinen Langerhanszellen 
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einen regulatorischen Einfluss auf die Degranulation von Mastzellen 
auszuüben.  
(2) Rosa26SmoM2YFP Mäuse wurden mit K5-CreERT und LangerinDTR:EGFP 
Mäusen gekreuzt, um einen Experimentenstamm (SmoM2LangerinDTR 
Mäuse) zu erhalten, in dem Basaliome induziert und Langerhanszellen 
depletiert werden können. Daher sind weitere Experimente über längere 
Behandlungszeiträume geplant.  
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1. Introduction 
 
 
1.1 The skin 
 
The skin is the largest organ of the vertebrate body, made up of multiple layers of 
tissue of ectodermal origin. The functions of the skin are various: it serves as a 
barrier to the surrounding environment, anatomically and immunologically protecting 
the body from pathogen entrance (Tomic-Canic 1998). It also serves as a 
somatosensory system via its different nerve endings. Furthermore, the skin plays a 
major role in body heat regulation, evaporation, water resistance, respiration, and 
synthesis and storage of lipids and water (Proksch 2008).   
Skin layers of mammals are referred to as epidermis, dermis and subcutis (Eckert 
1989) (figure 1). The human epidermis consists of five different layers: (1) stratum 
basale, (2) stratum spinosum, (3) stratum granulosum, (4) stratum ludicum, and (5) 
stratum corneum. On their way from basal layer to stratum corneum cells undergo 
morphological and biochemical changes, characterizing the transitional cell layers of 
the epidermis (Tomic-Canic 1998; Freedberg 2001). The major cell type of the 
epidermis is the keratinocyte (Nestle 2009), constituting more than 90% of the 
epidermis. 
In the stratum basale the stem cells of the epidermis reside. Cells of this layer are 
undifferentiated and possess the ability to proliferate. During asymmetrical cell 
divisions, daughter cells migrate outwards and differentiate along this route to 
replenish the stratum corneum. Terminal differentiation gives rise to fully keratinized 
cells. The stratum spinosum contains keratinocytes which still contain their nucleus, 
but already start to keratinize. Additionally, desmosomal junctions lead to the 
characteristical appearance of this epidermal layer, functioning as anatomical water 
barrier. In the stratum granulosum, keratinocytes are called granular cells, since they 
contain high amounts of keratohyalin and lamellar granules. Keratohyalin helps in cell 
dehydration for cell flattening and in aggregation and cross-linking keratin fibers for 
keratinization. Keratinocytes of the overlaying stratum ludicum are already flattened 
and dead. The outermost epidermal layer, the stratum corneum, is composed of dead 
cells lacking nuclei, which are highly keratinized, achieving an efficient prevention of 
water evaporation.  
Keratinocytes are known to have immunomodulatory function by either secretion of 
inhibitory cytokines like Interleukin (IL)-4 and transforming growth factor (TGF)β 
(Freedberg 2001), or release of pro-inflammatory cytokines like tumor necrosis factor 
(TNF)α or IL-1β (Tomic-Canic 1998; Freedberg 2001). The latter are capable of 
activating another cell type of the epidermis, the Langerhans cells. Other cells 
homing in the epidermis are Merkel cells, melanocytes and epidermal T cells.  
 
 
 
Fig. 1: scheme of skin morphology (adapted from Terese Winslow, National Institute of Cancer, 
Visuals Online) & network of epidermal immune cells (Langerhans cells and γδ T cells 
red: MHC-II; green: CD3ε; murine epidermis from the ear of a C57BL/6 mouse.  
 
Melanocytes, which are the pigment producing cells of the skin, are primarily resident 
in the basal cell layer in humans, whereas in mice they are mainly located in dermal 
regions surrounding the hair follicle (Bosenberg 2003). 
In mice, the skin resident T cell population expresses the alternative γδ T cell 
receptor (TCR), therefore called γδ T cells (Boismenu and Havran 1998; Laird 2009; 
Raulet 1989; Tigelaar 1990). They exhibit dendritic shape and, like Langerhans cells, 
form a network within the epidermis (figure 1). Their function remains unclear, but 
they are thought to be involved in innate immunity and wound healing (Toulon 2009).  
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1.2 Dendritic cells 
 
Dendritic cells (DCs) function as professional antigen-presenting cells (APCs) and  
are found in all tissues that are in close contact to the environment (intestine, lung, 
skin) (Naik 2007). They serve in antigen uptake, processing and presentation to T 
cells in lymph nodes (Cisse 2008). In mammals, two main divisions of DCs exist: 
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) (Asselin-Paturel and Trinchierl 
2005; Barchet 2005; Cao and Liu 2007). All murine DCs express the common 
surface marker molecule Cluster of Differentiation (CD)11c. The mDCs can be further 
divided into several subpopulations, characterized by expression of different surface 
molecules like CD4, CD8, CD11b or F4/80 (Shortman 2002).  
In mice, CD4+ DCs are the most prominent DC subtype in the spleen, and display 
only a minor fraction of lymph node DCs. CD4 is not only found on mDCs, but also 
known to be expressed on pDCs. CD8+ DCs are present in the spleen, as well as in 
skin-draining and mesenteric lymph nodes, but most prominent in the thymus. These 
cells are the only known DC subtype that does not express CD11b on its surface. 
Recent studies observed, that CD8+ DCs have the ability to induce a T helper 1 
(TH1)-biased cytokine response in reactive CD4+ T cells and produce valuable 
amounts of IL-12p70, whereas CD8−DCs tend to induce a T helper 2 (TH2)-biased 
response (Maldonado-López 1999, Moser 2000). The CD8 molecule is also 
expressed in low levels on LCs. Another molecule that is found on LCs is the F4/80 
surface marker, which is also present on macrophages and is thought to play in role 
in immunological tolerance (van den Berg 2005).   
 
 
1.2.1 Langerhans cells 
 
LCs are found in the epidermis, where they form a continuous network to take up 
foreign antigens via their extended dendrites (Merad 2008; Schuler 1993; Valladeau 
2005). It is believed that besides circulating haematopoietic precursor cells, a skin 
homing LC progenitor exists, which could not be identified so far (Gilliam 1998; Holt 
1994; Merad 2002). Although, several studies could show, that LCs repopulate 
locally independently of bone-marrow-derived progenitors in the steady state (Merad 
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2002). During inflammatory conditions, LCs derived from blood circulating monocytic 
precursors can also reconstitute the population (Merad 2004).  
Langerin (CD207) is a type II C-type lectin receptor that serves as a valuable marker 
for LCs in humans and mice and is involved in the uptake of pathogens (Valladeau 
2000). After internalization, Langerin is found in newly formed organelles called 
Birbeck granules, which are thought to function in antigen-processing (Birbeck 1961; 
Mc Dermott 2002; Wolff 1967). Other characterizing surface molecules of LCs are 
major histocompatibility complex (MHC) class II (MHC-II), CD11c, CD11b, E-
Cadherin, epidermal cell adhesion molecule (EpCAM), and F4/80 (Borkowski 1996; 
Stingl 1980; Tang 1993). In humans, LCs additionally express CD1a at high levels 
(Romani 2006). E-Cadherin serves as an epidermal anchorage protein that links LCs 
to the neighbouring keratinocytes. After antigen uptake LCs emigrate to skin-draining 
lymph nodes (sDLN) and present antigen to naive T cells (Stoitzner 2006). In 
migratory LCs, which constantly emigrate to LNs in the steady state, E-Cadherin is 
strongly downregulated, whereas CD11c, CD11b, EpCAM, and F4/80 expression 
remains stable (Jakob 2001). In contrast, MHC class II (MHC-II) as well as co-
stimulatory and migratory molecules like CD40 and C-C chemokine receptor (CCR)7 
are strongly upregulated (Karjalainen 2000; Ohl 2004; Pierre 1997). During 
inflammatory conditions, migration rate of LCs increases (Hemmi 2001; Macatonia 
1987; Stoitzner 2005). Migratory LCs can be found in the sDLN ~4 days after 
antigen-uptake in the epidermis (Kissenpfennig 2005).  
There are other dendritic cell subtypes present in the skin, referred to as dermal 
dendritic cells (dDCs) and further subdivided into Langerin+ and Langerin- dDCs.  
They do not only differ in expression of Langerin, but also in the presence of surface 
molecules CD11b, CD103, and F4/80 (Poulin 2007). Together, three different dDC 
subsets can be identified: Langerin-CD11b+, Langerin+CD11blow and Langerin-
CD11blow expressing DCs (Shklovskaya 2008). These dDCs show different migratory 
behavior than LCs, since after antigen uptake the migration of Langerin-CD11b+ and 
Langerin+CD11blow dDCs peaks after 1 day, whereas that of Langerin-CD11blow dDCs 
peaks at 2 days (Kissenpfennig 2005; Shklovskaya 2008). DDCs function in antigen 
presentation and chemokine secretion to initiate proinflammatory responses (Nestle 
2009). A scheme of skin APCs and their surface markers is depicted in figure 2.  
 
 
 
Fig. 2: schematic picture of skin immune cells of monocytic origin and their surface markers 
(from Merad, 2008).   
 
So far, controversial opinions exist among the scientific community about the 
immunological function of LCs. Dependent on experimental setup and immunological 
environment they may exhibit immunogenic or tolerogenic function. In vitro studies 
show that LCs isolated from human skin are capable of cross-presenting antigen to 
CD8+ T cells, as well as to induce a TH1 response (Klechenvsky 2008). Additional 
studies show that in contact-hypersensitivity response (CHS) LCs are required for 
cutaneous sensitization to haptens when antigen is administered to the epidermis 
(Stoitzner 2008). On the other hand, several studies suggest a role for LCs in 
tolerance: LCs induced deletional tolerance of self-reactive CD8+ T cells in a 
transgenic mouse model, in which keratinocytes expressed membrane-bound 
ovalbumin (Waithman 2007). Another study – using transgenic mice overexpressing 
CD40Ligand by keratinocytes – shows, that LCs activated in situ may break tolerance 
to tissue antigens, leading to systemic autoimmune disease (Mehling 2001).  
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1.2.2 Plasmacytoid dendritic cells 
 
The function of pDCs diverges from that of mDCs, since upon stimulation and 
activation pDCs produce large amounts of type I interferons, mainly interferon α 
(IFNα) (Cao 2009). Type I interferons are employed to stimulate macrophages and 
natural killer (NK) cells to elicit an antiviral immune response, as well as mDCs, B 
and T cells (Colonna 2004; Gilliet 2008; Piqueras 2006; Jego 2003; Le Bon 2003; 
Kolumam 2005). Characteristically, pDCs exhibit plasma-cell morphology and 
coexpress marker molecules B220, CD4, CD11c, GR-1, and MHC-II (Palamara 
2004). In mice, resting pDCs predominantly express Toll-like receptor (TLR) 7 and 
TLR9, both functioning in detection of nucleic acids in endosomal cell compartments 
(Cisse; Jarosay 2001). TLR7 can be stimulated by ssRNA molecules (Diebold 2001) 
and by members of a family of small molecules, the imidazoquinolines, to which the 
compounds Imiquimod and Resiquimod belong (Heil 2004; Jurk 2002). TLR9 
recognizes ssDNA molecules containing unmethylated CpG motifs (Hemmi 2000). 
Both TLRs are associated with the signal transduction protein MyD88, which serves 
as an adaptor molecule to transduce the signal via assembly of a protein complex 
composed of tumor necrosis factor (TNF) receptor associated factor (TRAF)6, 
Bruton´s tyrosine kinase (BTK), and interleukin-1-receptor-associated kinase (IRAK)4 
(Gilliet 2008).  Further downstream, this results in gene expression of 
proinflammatory cytokines IFNα, IFNβ, IFNλ, IFNω, IL-6, TNF, and costimulatory 
activation molecules CD40, CD80, and CD86 (figure 3) (Gilliet 2008; Kadowaki 
2001).   
 
 
Fig. 3: scheme of TLR7 or TLR9 induced activation of pDCs and TLR-downstream signaling 
(from Gilliet, 2008) 
 
 
1.3 Skin cancer 
 
Skin cancers are the most common malignancies in the white population. More than 
3.5 million skin cancers are diagnosed annually in the United States of America 
(Rogers 2010.). There are 2 main types of skin cancers: (1) melanoma and (2) non-
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melanoma skin cancer, which themselves are further subdivided into basal-cell 
carcinoma and squamous-cell carcinoma.  
 
 
1.3.1 Melanoma 
Melanoma accounts for only a small portion of all skin cancers, but is the type with 
the highest mortality since it exhibits a highly aggressive behavior and preferentially 
metastasizes to liver, lungs and brain. The etiology of melanoma is believed to arise 
from DNA damage caused by UV irradiation (Maddodi 2008), starting with a benign 
nevus that includes aberrantly proliferating melanocytes (Miller 2006). These 
hyperprofliferating cells lead to the formation of a hyperplastic lesion, which by 
overcoming senescence enters the next step in melanoma development: dysplasia 
(Gray-Schoper 2006; Mooi 2006). A dysplastic nevus can enter the radial growth 
phase (RGP), which is defined by superficial spreading, confinement to epidermis 
and low invasive potential. When cells gain the ability to invade the dermis, this stage 
is referred to as vertical growth phase (VGP) and is characterized by metastasis 
(figure 4) (Miller 2006).  
 
 
 
Fig. 4: scheme of the stepwise formation of melanoma, also showing characteristical genes to 
be mutated in this type of skin cancer (from Zaidi, 2008) 
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1.3.2 Basal-cell carcinoma  
Basal-cell carcinoma (BCC) is the most common type of skin cancer with an 
incidence of 30% of Caucasian developing BCC during their life (Epstein 2008; 
Gaitanis 2009). BCC is a rarely metastasizing type of non-melanoma skin cancer but 
still considered to be malignant. The appearance of BCC is a slow-growing, 
translucent, elevated lesion accompanied by telangiectasia and in most cases 
pigmentation (Rubin 2002). BCC can be subcategorized into three major groups: 
superficial BCC, nodular BCC and the aggressive infiltrative BCC. A molecular 
signaling pathway that is affected in a high percentage of BCCs is the Hedgehog 
(Hh) pathway (Gailani 1996; Xie 1998). In mammals there exist three different 
extracellular Hh ligands: sonic hedgehog (SHH), indian hedgehog (IHH), and desert 
hedgehog (DHH). All variants of Hh bind to the membrane receptor patched 
(PTCH1), which upon Hh binding releases its inhibitory function on another 
membrane protein called Smoothened (SMO). Once this inhibition is suppressed and 
SMO is recruited to the site of Hh interaction, it sends activating signals to 
suppressor of fused (SUFU) and further downstream to the members of the GLI 
transcription factor family: GLI1, GLI2, and GLI3 (Lum 2004). Since the Hh pathway 
interacts with other growth factor signaling pathways (EGFR, PDGFRα), and 
activates the PI3K-Akt, MAPK and Wnt pathways, it integrates many proliferative 
signaling cascades (Schnidar 2009; Xie 2001). UV irradiation is a major cause of 
DNA damage in the basal layer of the epidermis (Kricker 1995), leading to CT -> T 
and CC -> TT transitions, which are also referred to as ”UVB signature mutations“ 
(Lund and Timmins 2007). Mutations on human chromosome 9q22, where the 
PTCH1 gene is located, are known to be present in patients suffering from basal-cell 
nevus syndrome (or Gorlins syndrome) (Gailani 1992; Johnson 1996). These 
mutations are giving rise to a loss-of-function of the inhibitory activity of the PTCH1 
protein on the Hh pathway. Other Hh pathway affecting mutations were found in the 
smoothened (SMO) gene, an oncogene which, after point mutation, can acquire 
constitutive activity and lead to an active Hh signalling, thereby driving cell 
proliferation (figure 5) (Reifenberger 2005). Since UV-exposure also leads to damage 
and emigration of LCs from the epidermis and abnormal antigen-presentation of skin 
antigens, this inducible depression of the local immune system of the skin may 
depress immunosurveillance for tumor cells and additionally lead to DNA damage 
favoring skin cancer development (Granstein, 2004).   
 
 
Fig. 5: scheme of normal (A, left) and aberrant (B, right) Hedgehog signaling (from Epstein, 
2008) 
 
 
1.3.3 Squamous cell carcinoma  
Squamous-cell carcinoma (SCC) is a malignant tumour of the squamous epithelium 
of the epidermis. Like BCC it usually occurs in body regions which are exposed to 
sun light and is therefore thought to be caused by UV irradiation induced DNA 
damage. Also immunosuppression might be a risk factor for SCC. The metastasizing 
potential is low, but higher than for BCC (Clark 2008; Huang 2009). As previously 
shown by our lab, SCC survival is strongly dependent on EGFR signaling as well as 
on autocrine VEGFR signaling (Fig.6, Sibilia 2010). In a transgenic mouse model 
expressing a hyperactive form of the Ras activator Son of Sevenless (Sos) from the 
keratin5 promoter (K5-SOS mice), these mice develop spontaneous skin papillomas. 
K5-SOS activates expression of VEGFR, e.g. Flt1, and its ligands, resembling a 
situation similar to human SCC where overexpression of Flt1 can be observed 
(Bergers and Benjamin 2003, Ferrara 2003).  
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Fig. 6 Autocrine VEGF synergizes with EGFR in tumor cells to promote epithelial cancer 
development (Lichtenberger 2010).  
 
1.4.4 Skin cancer therapies 
Treatment of skin cancers includes (1) surgery, (2) cryotherapy, (3) photodynamic 
therapy, (4) chemotherapy and/or (5) immunotherapy, which may also be used in 
different combinations. For low-risk disease, chemo-, immuno- and cryotherapy are 
carried out to control the progression of the tumour. (1) Surgical techniques are 
subdivided into Moh´s micrographic surgery, simple or shave excision, 
electrodesiccation, laser surgery, dermabrasion, and cryosurgery. The most 
commonly used surgical method in skin cancer therapy is Moh´s excision, where the 
tumor is cut from the skin in thin layers. During surgery, the edges of the tumor and 
each layer of tumor removed are viewed through a microscope to check for cancer 
cells and to remove as little healthy tissue as possible. (2) Cryotherapy employs an 
instrument to freeze and destroy abnormal tissue. (3) For photodynamic therapy 
(PDT) a drug that is not active until it is exposed to light is injected into a vein. The 
drug collects more in cancer cells than in normal cells. When laser light is shined 
onto the skin the drug becomes active and cancer cells die. (4) Chemotherapeutical 
agents are commonly taken orally and lead to cancer cell death or inhibit their 
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proliferation. In case of skin cancer, these drugs are often applied topically to the 
tumor. (5) Immunotherapy involves topical treatment of cancer with Resiquimod or 
Imiquimod, thereby activating the immune system of the patient to induce tumor 
clearance.  
The compound Imiquimod is contained at a concentration of 5% in the cream Aldara 
and acts as an immune response modifier by binding to Toll-like receptor (TLR) 7 and 
the adenosin receptor A2A to activate signaling cascades of the innate immune 
system. TLR7 activation leads to release of pro-inflammatory cytokines like 
Interleukin (IL) 6, interferon (IFN) α, and tumor-necrosis factor (TNF) α (Hemmi 
2002). A TH1 response is initiated, recruiting CD8+ T cells with effector function to the 
site of Imiquimod application, thereby reducing the tumor volume (Huang 2009; 
Nakajima 2001). Recent studies showed that Imiquimod application leads to the 
activation and reversible emigration of LCs (De Giorgi 2009, Palamara 2004, Suzuki 
2000).  The immune cell infiltrate was shown to not only consist of CD8+ T cells, but 
also of additional cell types like natural killer (NK) cells, pDCs, macrophages and B-
cells (Miller 1999; Palamara 2004). There are more studies showing that Imiquimod 
exerts its antitumoural function independently of immunomodulation by either 
upregulating opioid growth factor receptor (OGFR) expression (Zagon 2008), leading 
to inhibition of cell proliferation, or via upregulation of Bax (Schön 2004), promoting 
enhanced tumour cell apoptosis.  
 
1.5 Mouse skin cancer models 
There exist different models to study melanoma initiation and progression: (1) UVR-
induced melanoma (Noonan 2001); (2) graftment of human melanoma onto 
immunocomprimised mice (Berking 2004); (3) murine melanoma derived from 
autochthonous murine or genetically engineered mouse (GEM) tumors transplanted 
into immunocompetent syngeneic mice (Fidler and Kripke 1977); (4) GEM melanoma 
with similar history to human disease (Ackermann 2005; Chin 2006; Gupta 2005); 
and (5) graftment of murine melanoma to GEM hosts (Yu 2002) (figure 6).  
Animal models for BCC include mice with deficiency in PTCH1 (Corcoran 2001; Hahn 
1997) or activating mutations in SMO (Mao 2006), leading to a constitutively active 
Hh signaling pathway, thereby driving cell proliferation.  
 
 
 
Fig 7.: different mouse models for melanoma studies (from Zaidi, 2008) 
 
 
1.6 Mouse models used 
Two different mouse model systems were chosen: (1) to study whether Imiquimod is 
still therapeutically active in the absence of LCs after intradermal injection of B16F10 
melanoma cells into syngeneic LangerinDTR:EGFP mice; and (2) to study the role of 
LCs in BCC treatment, mice harboring a constitutively active form of the smo gene, 
SmoM2, were treated with Imiquimod. As this study requires mice with an intact 
immune system without any compromission and also a normal stroma, both mouse 
models were of C57BL/6 background.  
 
(1) The B16 murine melanoma and its individual sublines were generated by 
Fidler and Kripke in 1977. B16F10 melanoma cells were intradermally injected 
into LangerinDTR:EGFP mice, which harbor a transgene consisting of the 
sequence of the human diphteria toxin (DT) receptor (DTR) fused to the 
sequence of enhanced green fluorescent protein (EGFP) under the control of 
the murine langerin promoter (figure 7). When DT is injected intraperitonially 
(i.p.) to mice, DT will be able to enter all cells, which express the DTR and 
induce their apoptosis. DTR expression thereby enables uptake of i.p. applied 
DT to deplete Langerhans cells from murine skin. A limitation of this system is 
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given by the fact, that not only the LCs are depleted of the skin, but also the 
langerin-expressing dDCs.  
 
 
Fig. 8: scheme of the LangerinDTR:EGFP transgene 
 
(2) The BCC model employs Smoothened transgenic mice, harboring a 
constitutively active form of the smo gene, called SmoM2, under the control of 
the ubiquitously expressed Rosa26 locus. In front of the smoM2 gene a 
Neomycin stop-cassette is inserted, which is flanked by LoxP sites. These 
mice were crossed in the C57BL/6 background to mice harboring a Keratin5 
(K5) CreERT (K5-CreERT) transgene. K5 is mainly expressed in the basal layer 
of the skin. By injecting tamoxifen to these mice, Cre recombinase can 
translocate to the nucleus and remove the floxed stop-cassete. Thereby 
expression of the hyperactive smo gene is induced, resulting in development 
of skin alterations similar to BCC in these mice.  
R26SmoM2:YFP mice were also crossed to LangerinDTR:EGFP mice to allow 
development and progression of BCC in WT and LC depleted mice.  
 
 
Fig. 9: breeding scheme of mice harboring the R26SmoM2:YFP transgene and mice 
harboring the K5-CreERT transgene.  
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2. Aim of thesis  
 
Since Langerhans cells (LCs) exert a profound role in skin immunology, my study 
adressed the question, which impact LCs have on skin cancer growth and if they are 
necessary for Imiquimod´s action as an anti cancer drug. As recent studies confirmed 
an activation of LCs upon Imiquimod treatment and enhanced infiltration of pDC-like 
cells to the site of topical Imiquimod application (Palamara 2004), there might be a 
correlation between both events.   
To answer, whether there is a correlation of LC-presence and tumor growth during 
Imiquimod treatment, LangerinDTR:EGFP mice were subcutaneously injected with 
B16F10 melanoma cells. Tumor growth was monitored in WT mice and mice 
depleted of LCs, as well as in Imiquimod treated WT and LC-depleted mice to 
observe possible effects of LC on tumor progression. Tumors were examined 
histologically for infiltrating immune cells, especially pDC-like cells and T cells, since 
these cell populations are thought to play a major role in antitumoral immune activity.  
During my study, I established a second mouse model system of skin cancer 
in the lab: R26SmoM2:YFP mice were crossed to K5-CreERT transgenic mice to allow 
development and progression of basal-cell carcinoma (Ref). To further be able to 
study the role of LCs in this model, these mice were crossed to LangerinDTR:EGFP 
mice. After development of BCC lesions, mice were treated with Imiquimod to reveal 
its antitumoral activity in this model. Tumor growth and characterization of skin 
morphological changes were monitored histologically. The distribution of epidermal 
immune cell was analyzed by immunofluorescence staining on frozen sections.  
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3. Results  
 
3.1 Effect of Imiquimod on WT murine skin 
 
To evaluate the ability of Imiquimod to activate LCs not only in humans (De Giorgi 
2009), but also in mice, ears of C57BL/6 wilde-type (WT) mice were creamed with 
Aldara for seven consecutive days and analyzed by histology and FACS. 
Immunofluorescence staining of epidermal ear sheets for langerin revealed an 
activated morphology of LCs: cells had less dendrites, contained a larger cell body 
and an increased staining intensity for MHC-II was observed (figure 10). The total 
number of LCs in the Imiquimod-treated ears decreased compared to non-treated 
ears, confirming an emigration of activated LCs from the epidermis (Palamara, 2004).  
 
Fig. 10: Imiquimod leads to activation and emigration of Langerhans cells from mouse ears 
after 7 days of consecutive Aldara-treatment. A, B: epidermal ear sheets from untreated (A) and 
Imiquimod treated (B) mice stained for Langerin; C: quantification of total LCs and percentage 
of activated LCs. n = 3; scale = 100µm  
Green: Langerin 
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FACS analysis also showed infiltration of several new immune cell populations, 
especially myeloid cells expressing the CD11b and CD11c surface molecules, as well 
as cells expressing mPDCA-1 and Ly6C into Imiquimod-treated ears (figure 11). 
 
 
 
Fig. 11: FACS plots showing stainings for CD11b, CD11c, Ly6C, and mPDCA-1 from 7 days 
untreated and Imiquimod-treated adult WT mouse ears, gated on CD45 positive hematopoietic 
cells. It is shown that Imiquimod treatment leads to infiltration of CD11b+, Ly6C+ and mPDCA-1+ 
cells into the dermis of mouse ears.   
 
These findings confirm that LCs of C57BL/6 mice react to topical Imiquimod 
application and may lead to immune cell recruitment to the site of treatment. To 
investigate, whether the infiltrative effect of Imiquimod is altered in the absence of 
LCs in the epidermis, LangerinDTR:EGFP mice were depleted of LCs and creamed 
with Aldara on ears for seven consecutive days. The skin infiltrate was then analyzed 
by FACS to determine if an immune cell infiltrate can be observed in LC depleted 
mouse skin after Imiquimod treatment.  
Imiquimod treatment results in an infiltrate of monocytes into the dermis. I could 
observe that in the absence on LC this infiltrate of CD11b+Gr-1+CD115+ cells was 
more than doubled (Fig.12A). Additionally, the number of CD8ε+ cells infiltrating into 
the skin was increased compared to mice treated with Imiquimod in the presence of 
LC. These CD8 ε + cells were mainly MHCII+ and only few of them were CD8 ε + T-
cells (Fig.12B). No impact on the infiltrate of pDC like cells could be observed in the 
absence of LC. These results demonstrate that immunomodulatory effects of 
Imiquimod are not dependent on the presence of LCs in the epidermis.  
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Fig.12: Flow cytometric analysis of skin cell suspensions. A: increased number of CD115/Gr-1 
DP cells in  LC depleted, Imiquimod treated skin; gated on CD11b high hematopoietic cells. 
B: Increased number of MHC II+ cells in Imiquimod treated skin (left). Among these there is a 
higher percentage of CD8ε+ cells in LC depleted, Imiquimod treated skin (right, gated on MHCII 
/ CD45 DP cells).  
 
 
To further analyze the effect of LCs on skin cancer growth and during skin cancer 
treatment with Imiquimod, I made use of the LangerinDTR:EGFP mouse model 
intradermally injected with B16F10 melanoma cells.  
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3.2 Effect of LCs on B16F10 melanoma growth 
 
 
3.2.1 Tumor growth 
 
In case of skin cancer, the Imiquimod induced immune cell infiltrate may lead to an 
effective killing of tumor cells, resulting in stagnation or even regression of tumor 
growth (Palamara 2004). To address the question, whether LCs contribute to the 
Imiquimod effect, 3.5.104 B16F10 melanoma cells per mouse were intradermally 
injected into LangerinDTR:EGFP knock-in mice. Mice were separated into four 
experimental groups: (1) untreated; (2) LC-depleted by DT injection; (3) Imiquimod-
treated; and (4) LC-depleted by DT injection and Imiquimod-treated. DT injections 
were started when tumors were about 3.5 mm in diameter with a concentration of 
200ng of DT per mouse. DT injections were repeated every fourth day, to exclude a 
replenishment of the skin with Langerin+ cells (dDCs as well as LCs) during tumor 
growth and/or Imiquimod-treatment. Aldara-treatment was started 1-2 days after LC 
depletion (when tumor size was about 4 – 4.5 mm in diameter), ensuring that DT- 
and Imiquimod-treated mice were already depleted of LCs when Imiquimod 
application occurred. Imiquimod application to tumor overlaying skin was performed 
every second day until mice were sacrificed. Tumor size was measured every second 
day to evaluate the growth rates of tumors from all four mouse groups (Fig. 13).  
 
 
 
Fig. 13:  Time scale of tumor treatment in the B16F10 melanoma model in LangerinDTR:EGFP 
mice.  
 
Efficient depletion of LCs was confirmed by preparation of epidermal ear sheets 
stained for MHC class II molecules at the end of the experiment (figure 14). MHC-II 
negative sheets show an efficient depletion of Langerin+ cells in the epidermis.   
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Fig. 14: LCs are efficiently depleted from the epidermis after DT treatment, confirmed by 
immunofluorescence staining of epidermal ear sheets 24-36 hours after the last injection of DT; 
A: untreated mouse; B: DT treated mouse. n = 4-7 mice of 2 independent experiments. scale = 
100µm 
Green: MHC-II; Blue: Hoechst 
 
Tumor growth was not altered in LC-depleted mice compared to untreated WT mice, 
leading to the conclusion that LC function is not required to decelerate tumor 
proliferation. Imiquimod-treated WT mice showed a significantly slower tumor growth 
rate compared to untreated WT mice, showing that application of Aldara leads to an 
effective antitumoral reaction (figure 15). Interestingly, an Aldara effect was also 
observable in mice depleted of LCs and treated with Imiquimod compared to both 
untreated WT mice and LC-depleted mice. These findings suggest that Imiquimod 
acts in the absence of LCs and Langerin+ dDCs.  
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Fig. 15: LCs are not responsible for the mediation of the antitumoral effect of Imiquimod. 
Graphs shows B16F10 melanoma tumor growth curves in untreated (blue), LC depleted (black), 
Imiquimod treated (red) and LC depleted Imiquimod-treated (green) mice. Graph shows results 
of a representative experiment out of three independent experiments; n = 4-7 mice. 
 
 
3.2.2 Immune cell infiltrate into B16 melanoma 
 
It was reported previously from our lab, that different subtypes of immune cells are 
infiltrating the skin sites where Imiquimod is applied and also Imiquimod treated 
melanomas (Palamara 2004). To confirm these data in C57BL/6 mice for the B16F10 
tumor model and to characterize the immune cell infiltrate into tumors of mice 
depleted of Langerin+ cells immunofluorescence stainings were performed on frozen 
sections, making use of several immune cell markers (figure 16).  
Costaining of CD4 and CD3ε on sections from B16F10 tumors revealed considerably 
higher numbers of CD4 single positive (SP) cells compared to CD4/CD3ε double 
positive (DP) cells in all mice, indicating that most CD4+ infiltrating cells were not 
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CD4+ T cells (figure 16A,D,G,J). Indeed, Imiquimod-treated WT mice showed a 
significantly increased CD4+ cell infiltrate compared to untreated WT mice. 
Interestingly, although an Aldara effect was observed, an increased CD4+ cell 
infiltrate could not be detected in LC-depleted Imiquimod-treated mice (figure 17A). 
Among the CD4/CD3ε DP T cells there were no differences in infiltrating cell numbers 
detectable (figure 17B).  
To detect, whether the CD3ε- /CD4+ cells were DCs, costaining of MHC-II and CD4 
was performed (figure 16B,E,H,K). Imiquimod-treated WT mice showed a significant 
increase in infiltrating CD4/MHC-II double-positive cells compared to LC-depleted 
Imiquimod-treated mice (figure 17C). This finding indicates that LCs are required for 
recruitment of CD4/MHC-II double-positive (DP) cells to the site of Aldara application, 
but that these DP cells do not seem to be important for the Imiquimod effect on tumor 
growth.  
Since recent publications showed that Imiquimod treatment leads to massive 
infiltration of CD8+ T cells into human skin cancer, followed by tumor clearance, 
immunofluorescence costainings of CD8 and CD3ε were performed on frozen 
sections of B16F10 tumors (figure 16C,F,I,L). Quantification of the total number of 
CD8+ cells revealed comparable numbers among all four mouse groups (figure 17D). 
However, Imiquimod treated WT mice showed higher CD8+ T cell numbers in 
B16F10 melanoma compared to untreated WT controls. This increase could not be 
observed in the absence of Langerin+ cells since CD8+ T cell numbers in Aldara 
treated WT mice were also higher than in tumors from LC-depleted Imiquimod 
treated mice (figure 17E). From these data it may be concluded that Langerin+ cells 
seem to be required for priming of cytotoxic CD8+ T cells. Surprisingly, like for 
CD4/MHC-II DP cells, the influx of CD8/CD3ε DP cells into the tumors does not seem 
to be essential for Imiquimod dependent reduced tumor growth.  
  
Fig 16: Langerhans are required for recruitment of MHCII/CD4 DP and CD8+ T cells into B16F10 
tumors upon Imiquimod application to tumor overlaying skin. A, B, C: tumor sections from 
B16F10 bearing untreated WT mice; D, E, F: tumor sections from B16F10 bearing Imiquimod 
treated WT mice: G, H, I: tumor sections from B16F10 bearing LC-depleted mice; J, K, L: tumor 
sections from B16F10 bearing Imiquimod treated LC-depleted mice. scale = 100µm, arrows 
pointing on double positive cells in the respective staining: 
A, D, G, J – Green: CD4, Red: CD3e, Blue: Hoechst 
B, E, H, K – Green: CD4, Red: MHCII, Blue: Hoechst 
C, F, I, L – Green: CD8a, Red: CD3e, Blue: Hoechst  
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C 
Fig. 17: Quantification of  cellular composition of the immune cell infiltrate of B16F10 
melanoma grafted tumors. A: CD4 SP cells; B: CD4+ T cells; C: MHCII CD4 DP cells; D: CD8 SP 
and E: CD8+ T cells. n = 4-7 mice of 2 independent experiments.  
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3.2.3 Skin morphology and mast cell infiltration 
 
I have shown that Imiquimod acts on melanoma growth in mice even in the absence 
of LCs although the immune cell infiltrate is perturbed. To better understand the 
mechanism of action of Imiquimod in the absence of LCs I took a closer look at the 
direct effects of Imiquimod on the skin. 
 Histological stainings with H&E showed epidermal thickening in mouse skin treated 
with Imiquimod, independently of the presence of LCs (figure 18A,C,E,G). Both, WT 
and LC depleted Imiquimod treated mice exhibited a significant increase in epidermal 
thickness compared to their untreated counterparts (figure 19A). This result indicates 
a direct action of Imiquimod on keratinocytes, thereby leading to acanthosis.  
A recent study (Schild 2007) showed that the function of Imiquimod is exerted by 
activation of mast cells. Activated, degranulating mast cells in turn are claimed to 
activate LCs. Giemsa stainings performed on paraffin sections of B16F10 tumor 
overlaying skin (figure 18B,D,F,H) confirmed that tumor overlaying skin in all 
Imiquimod treated mice contained increased numbers of mast cells, independently of 
the presence of LCs (figure 19B). Imiquimod-treated WT mice showed a trend 
towards increased degranulation of mast cells compared to untreated control 
animals, but this difference was statistically not significant. In contrast, LC-depleted 
Imiquimod-treated mice showed statistically significant higher rates of degranulated 
mast cells compared to untreated LC-depleted controls (figure 19C). Putting these 
data together Imiquimod seems to stimulate mast cells to degranulate. This reaction 
might be antagonized by LCs, thereby influencing the immunogenicity of the 
inflammatory environment.  
 
Taking all data together, it can be concluded, that LCs are not the mediators of the 
anti-tumoral effect of Imiquimod. B16F10 tumor growth is reduced in Imiquimod 
treated LC-depleted mice in the same extent as it is observed in LC-containing 
control mice. Although absence of LCs from the epidermis seems to result in a 
reduced recruitment of CD8+, CD4+ and MHC-II/CD4 DP cells to the skin when 
compared to WT mice. The lack of these tumor infiltrating immune cells does not 
seem to impair the anti-tumoral action of Imiquimod.   
 
 
 
  
 
Fig. 18: Morphology and mast cell numbers of tumor overlaying skin from B16F10 grafted 
LangerinDTR:EGFP mice. A, C, E, G: Histological stainings with H&E; B, D, F, H: histological 
stainings using Giemsa stain, grey arrows pointing on mast cells. scale = 100µm 
Abbreviations: E – epidermis; D – dermis; HF: hair follicle   
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Fig 19: Histological analysis of tumor overlaying skin from B16F10 tumor bearing 
LangerinDTR:EGFP mice. A: Quantification of  measurement epidermal thickness, B: 
quantification of total skin mast cell numbers; C: counts of degranulated skin mast cells.  
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3.3. Influence of presence of BCC on skin microenvironment 
 
 
3.3.1 Breeding and treatment of mice 
 
Imiquimod is most successfully used in humans to treat BCC. To develop a model, 
where the mechanisms underlying the successful therapy of BCC using Imiquimod 
can be studied, I utilized an inducible model of BCC by first crossing SmoM2YFPfl/fl 
mice to K5CreERT/+. These SmoM2YFPfl/fl K5CreERT/+ mice were further crossed to 
LangerinDTR:EGFP mice to generate SmoM2YFPfl/+ K5CreERT/+  
LangerinDTR:EGFP mice (further referred to as SmoM2LangerinDTR mice), which 
allow to study the role of LCs in BCC development and progression. Goal of the initial 
experiments was to establish protocols for BCC-induction and to address whether 
BCC-treatment with Imiquimod in LC containing SmoM2LangerinDTR mice is 
comparable to treatment in humans. 
Induction of Cre-recombination was performed according to the published protocol 
(Mao 2006), starting at postnatal day 10 (P10) by injection of tamoxifen for 5 
consecutive days, leading to expression of smoM2. Mice were continuously given 
tamoxifen once a week after induction of Cre expression. At ~ day 45 neoplastic 
changes could be observed microscopically in the skin of SmoM2LangerinDTR mice 
(data not shown), whereas macroscopically visible BCC lesions developed by day 80 
to day 90. Therefore the timepoint of day 90 was chosen to start Aldara treatment of 
BCC. Analogous to the human schedule, mice were treated for 5 consecutive days 
with Imiquimod (Aldara patient package insert 2009), followed by two days of 
recovery, followed by 5 days of treatment (figure 20). As in mice BCC is most 
prominently visible at ears and tail, ear biopsies were taken at day 90 (further 
indicated as experimental day 0), and were compared to ear biopsies obtained at the 
end of the experiment (experimental day 12). Ears of both timepoints were then 
compared to monitor disease progression in untreated and Aldara-treated mice. After 
the second week of Aldara application, photographs of ears and tails were taken and 
mice were sacrificed at experimental day 12 (figure 21).  
 
 
 
Due to a lack of time during the thesis, no LC depletion experiments could be 
performed during this project. It is still necessary to evaluate the effect of LC 
presence on BCC growth, but also on BCC development. Therefore DT injections 
need to be started at different timepoints: for investigating the role of LCs on BCC 
growth LC depletion needs to be initiated by day 88. Analyzing the effect of LCs on 
BCC development requires LC depletion starting by day 10.  
 
 
 
Fig. 20: time schedule of BCC induction by tamoxifen in SmoM2LangerinDTR mice and 
Imiquimod treatment.  
 
 
To analyze BCC growth during my thesis, I processed the skin of ears and tails for 
histological analysis and characterized these tissue biopsies by immunofluorescence 
stainings, H&E and Giemsa stainings.  
Macroscopical analysis of BCC bearing mice showed that severity of BCC was 
diverging from individual to individual (figure 20). It also indicated that Imiquimod 
treatment for 2 weeks did not lead to disease clearance, as BCC lesions were still 
visible on ears and tails of SmoM2LangerinDTR mice.  
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Fig. 21: Macroscopioc images from ears and tails of healthy and BCC bearing mice at 
experimental day 12; arrows showing BCC lesions in age matched SmoM2LangerinDTR mice.  
n = 2-3 of 2 independent experiments.  
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3.3.2 Skin morphology and skin mast cell infiltration 
 
Figure 22 shows H&E stainings from ear sections of unaffected and BCC bearing 
mice. Healthy SmoM2LangerinDTR mice treated with Imiquimod show signs of 
acanthosis on day 12 (figure 22A-D), indicating that Imiquimod has acted properly on 
BCC unaffected skin.    
In the third row an ear section of untreated SmoM2LangerinDTR mice is shown, 
demonstrating branched basal cell layer protrusions into the dermis, accompanied by 
increased melanocyte location to BCC formations (figure 22E-H, indicated by green 
arrows). Neoplastic morphological changes of the basal cell layer are most obvious in 
interfolicular epidermis and the infindibulum. Furthermore the epidermis in BCC 
bearing SmoM2LangerinDTR mice exhibits an increase in diameter compared to 
healthy epidermis (figure 23). Large blood vessels can also be noticed in close 
proximity to foci of neoplastic skin (figure 22E-H). Comparison of skin morphology of 
experimental day 0 and day 12 shows that neoplastic foci of untreated, as well as of 
Imiquimod treated BCC bearing mice are increasing over time (figure 22E-H). The 
progression of BCC growth is accompanied by melanocyte aggregation in the dermis.  
BCC bearing mice treated with Imiquimod still harbor neoplastic lesions in their skin 
at day 12, showing that the disease is not regressing after a 2 week treatment.  
Like in the B16F10 melanoma experiments, an effect of Imiquimod treatment on 
epidermal thickness can be observed: application of Aldara leads to induction of 
acanthosis. Aldara creamed ears show significantly increased epidermal thickness at 
day 12 compared to day 0 after treatment in healthy and in BCC bearing 
SmoM2LangerinDTR mice (Fig. 17C-D, 17G-H). This indicates that Aldara exerts 
keratinocyte activating function not only in normal, but also in BCC affected skin.  
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Fig. 22: skin morphology of healthy and BCC bearing mouse ears. Imiquimod treatment for 2 
weeks does not lead to regression of BCC. A, C, E, G: H&E stainings of ear sections on 
experimental day 0; B, D, F, H: H&E stainings of ear sections on experimental day 12, green 
arrows indicating melanocytes, black arrows indicating basal-cell carcinoma like structures 
branching into to dermis. scale = 100µm 
Abbreviations: E-  epidermis, D – dermis  
 
Fig. 23: diagram of measurement of epidermal thickness in healthy and BCC bearing mice 
comparing experimental day 0 amd day 12. n = 2-3 mice per group. 
 
 
As H&E stainings of BCC bearing ears showed an infiltrate into the dermis, I further 
wanted to analyze, whether presence of BCC or Imiquimod treatment have an effect 
on mast cell numbers and degranulation in this tumor model. Giemsa stainings reveal 
increased numbers of total and activated mast cells in ear skin of untreated BCC 
bearing mice compared to untreated WT animals (figure 24A-B, 24E-F). This 
indicates that BCC progression leads to mast cell infiltration and degranulation. BCC 
unaffected SmoM2LangerinDTR mice treated with Imiquimod for 12 days exhibit 
significantly increased numbers of activated mast cells compared to day 0. In 
contrast, BCC affected skin contains more mast cells independently of Imiquimod 
application (figure 25). Therefore I conclude that Imiquimod application does not 
affect mast cell degranulation in presence of BCC. Whether this is due to release of 
anti-inflammatory factors from keratinocytes or to suppressive function of Imiquimod-
induced infiltrating immune cells is under investigation. 
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Fig. 24: Giemsa staining on histological sections of healthy and BCC bearing mouse ears. 
Presence of BCC leads to increased mast cell numbers. A, C, E, G: Giemsa stainings of ear 
sections on experimental day 0; B, D, F, H: Giemsa stainings of ear sections on experimental 
day 12, grey arrows indicating mast cells, black arrows indicating basal-cell carcinoma like 
structures branching into to dermis. scale = 100µm 
Abbreviations: E-  epidermis, D – dermis, HF – hair follicle, M – mast cell, C – cartilage   
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Fig. 25: total number of mast cells as well as degranulated number of mast cells increases after 
2 weeks in untreated BCC bearing mice. A: quantification of total mast cell numbers in ear skin 
of healthy and BCC bearing mice;  B: quantification of degranulated mast cell numbers in ear 
skin of healthy and BCC bearing mice. n = 2-3 mice per group. 
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3.3.3 Epidermal LC distribution  
 
Several recent publications show an alteration of epidermal immune cell distribution 
in human skin affected by BCC (Santos 2010, Mardones 2009). These studies claim 
a high density of LCs in peritumoral areas, whereas LCs seem to be absent from 
tumor overlaying skin. To investigate, if this phenomenon is also seen in the 
SmoM2LangerinDTR mouse model, immunofluorescence staining using antibodies 
against Langerin and MHC-II was performed on epidermal ear sheets at day 0 from 
unaffected and BCC affected mice (figure 26A-B). Morphological differences of LCs 
between WT and BCC bearing mice can be seen – LCs in BCC bearing ears appear 
smaller in contrast to LCs from unaffected skin. Second, like in humans, a 
rearrangement of the LC network in BCC affected skin is observable – LCs from BCC 
bearing ears partially cluster and show a decrease in the intensity of MHC-II 
expression. In some areas of the ear keratinocytes of BCC bearing mice exhibit 
expression of MHC-II (figure 26B). These areas are considered to be inflamed. LC 
allocation in BCC affected SmoM2LangerinDTR ear epidermis shows striking 
differences between MHCII+ keratinocyte areas and MHC-II- keratinocyte areas: LC 
density in MHCII+ keratinocyte areas is increased, whereas it is found to be 
decreased in MHCII- keratinocyte areas (figure 26C). These results indicate that 
keratinocytes are inflamed and that LCs are activated and redistributed in BCC 
affected skin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26: LCs are redistributed in the epidermis of BCC bearing mice compared to healthy mice. 
A: immunofluorescence staining of ear sheets, showing a representative healthy mouse ear, B: 
immunofluorescence staining of ear sheets, showing a representative BCC bearing mouse ear; 
C: quantification of LCs in ear areas of keratinocytes negative or positive for MHCII. n = 2-3 
mice per group. scale = 100µm 
Green: Langerin; Red: MHC-II 
 
 
 
 
 
 
 
52 
 
53 
 
3.3.4 Immune cell infiltration into skin 
 
The finding of redistribution of activated epidermal immune cells can also be seen in 
immunofluorescent stainings on cryosections from ears of SmoM2LangerinDTR mice 
(figure 27, 28). According to disease severity skin areas were classified into “strong” 
and “mild” BCC. As already seen in en face view on epidermal ear sheets from 
unaffected and BCC affected SmoM2LangerinDTR mice, cryosections showed 
different distribution of epidermal immune cells in BCC affected mice compared to 
WT mice. LCs, as well as γδ T cells were mostly absent from epidermal regions 
directly overlaying prominent BCC formations, whereas they were found in normal 
numbers in peritumoral (mildly affected) or healthy skin regions (figure 27B-C, figure 
28B-C). These results suggest that similar to the human situation in the 
SmoM2LangerinDTR model peritumoral skin is inflamed and contains increased 
numbers of immune cells like LC and γδ T cells whereas in the skin directly 
overlaying the tumor immune cells are rather reduced (figure 27G, 28G).  
This alteration of LC distribution is not influenced by application of Imiquimod (figure 
27E-F, figure 28E-F).  
The immunofluorescence staining also showed that development of BCC leads to 
infiltration of CD3ε+ and MHCII+ immune cells into the dermis. Microscopical analysis 
suggests that the intensity of infiltration is enhanced upon Aldara treatment (figure 
27E, 28E). Imiquimod application onto healthy skin for 2 weeks is also accompanied 
by increased immune cell infiltration into the dermis (figure 27D, 28D). I therefore 
conclude, that in a 2 week Imiquimod treatment of BCC in the SmoM2LangerinDTR 
mouse model, Aldara application leads to an increased recruitment of MHCII+ cells or 
T cells compared to untreated mice.  
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 27:  Distribution of LCs in BCC affected skin is altered: Immunofluorescence stainings 
on cryosections from healthy and BCC bearing mice treated and untreated with Imiquimod; A: 
untreated healthy mouse, B: untreated BCC showing a strong phenotype, C: untreated BCC 
showing a mild phenotype, D: Imiquimod treated healthy mouse ear, E: Imiquimod treated BCC 
showing a strong phenotype, F: Imiquimod treated BCC showing a mild phenotype; G: 
quantification of LC numbers in epidermis overlaying BCC of strong and mild phenotype. n = 2-
3 mice per group. scale = 100µm 
Green: Langerin; Red: MHCII; Blue – Hoechst   
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Figure 28:  Distribution of γδ T cells in BCC affected skin is altered: Immunofluorescence 
stainings on cryosections from healthy and BCC bearing mice treated and untreated with 
Imiquimod; A: untreated healthy mouse, B: untreated BCC showing a strong phenotype, C: 
untreated BCC showing a mild phenotype, D: Imiquimod treated healthy mouse ear, E: 
Imiquimod treated BCC showing a strong phenotype, F: Imiquimod treated BCC showing a 
mild phenotype; G: quantification of γδ T cell numbers in epidermis overlaying BCC of strong 
and mild phenotype. n = 2-3 mice per group. scale = 100µm 
Green: Vγ3; Red: CD3ε; Blue - Hoechst 
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4. Discussion 
 
Since skin cancers appear with a high incidence (Rogers 2010), it is of importance to 
study the mechanisms underlying their development and progression. Therefore, 
many different mouse model systems have been established to examine the impact 
of a diversity of factors on skin cancer formation (Zaidi 2008). In contrast to BCC, 
melanoma is a highly aggressive type of skin cancer and often leads to death of 
patients. During the last decades, different mechanisms of induction of these cancers 
could be unraveled, resulting in better therapies for patients. One therapeutic agent 
commonly used for control and clearance of skin tumor growth is the small immune 
response modifier Imiquimod, which acts as a TLR7 agonist to activate immune cells, 
resulting in tumor regression especially in BCC patients. Human data suggest that 
Imiquimod, when topically applied to the skin, activates LCs. Therefore this study 
tries to evaluate whether the activation of LCs is crucial for the therapeutic effect of 
Imiquimod.  
In my study, two different mouse model systems were chosen to answer this 
question: (1) the B16F10 melanoma model in LangerinDTR:EGFP mice, and (2) the 
SmoM2:YFP K5CreERT LangerinDTR:EGFP mice developing BCC.  
LangerinDTR:EGFP can be efficiently depleted of LCs from the epidermis, thereby 
monitoring cancer growth in mouse skin lacking LCs.  
LC presence does not influence tumor growth of B16F10 melanoma cells in 
LangerinDTR:EGFP mice. Mice depleted of LCs exhibit the same tumor growth rates 
as WT mice do, suggesting that the tumor progression is independent of the 
presence of LCs.  Aldara-treatment of B16 melanoma of WT and LC-depleted mice 
results in reduced tumor growth rates in both animal groups compared to untreated 
control groups. This outcome leads to the conclusion that LCs are not required to 
mediate the anti-tumoral effects of Imiquimod.  
Since it is commonly accepted that immunosuppression in the skin, e.g. mediated by 
UV irradiation, is associated with a higher risk for skin cancer development, the role 
of LCs in the B16 melanoma model needs to be evaluated under additional 
conditions: LC depletion needs to be performed prior to the subcutaneous injection of 
B16 melanoma cells and sustained until the end of the experiment. This experiment 
gives answer to two questions: (1) do B16 tumors form earlier in LC depleted mice, 
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and (2) does Aldara still exhibit its antitumoral effect in mice which have been 
depleted of LCs prior to melanoma formation?  
Although absence of LCs resulted in minor infiltration of tumors by pDC-like MHC-II 
CD4 DP cells, CD4+ and CD8+ cells after Aldara treatment, tumors in LC depleted 
mice still respond to Imiquimod treatment. Therefore it can be concluded that under 
the given conditions, pDC-like cells, as well as CD4+ and CD8+ cells, are at least not 
alone responsible for mediating the Imiquimod effect.  
Analysis of mast cells revealed an increase in total mast cell numbers in both 
Imiquimod treated WT and LC-depleted mice. Since mast cells are known to be 
activated by treatment with Aldara cream (Schild 2007), an increase in degranulated 
mast cells can be observed after Imiquimod application to tumor overlaying skin. A 
significant difference in the amount of activated mast cells can only be observed 
between untreated LC-depleted mice and Aldara creamed LC-depleted mice, 
indicating that the presence of LCs seems to dampen the process of mast cell 
degranulation.  
Since the LangerinDTR:EGFP mice harbor the sequence for the DTR under control 
of the murine Langerin promoter, not only LCs are efficiently depleted of the skin, but 
also Langerin expressing dDCs. To exactly evaluate the role of LCs in this model 
system, a mouse model needs to be found, which depletes only LCs from the skin 
compartment, and not additional Langerin+ dDCs as well. One such model would be 
the generation of bone-marrow chimeric mice containing WT bone marrow in 
LangerinDTR:EGFP mice.  
The development of SmoM2:YFP mice (McMahon 2002) gave the opportunity to 
study the role of the Hedgehog pathway in different cancer types: BCC, 
rhabdomyosarcoma, and medulloblastoma (Epstein 2008). This pathway is often 
affected in human BCC patients (~90%) and therefore a major component in control 
of tumor formation and progression. To establish a BCC mouse system, SmoM2:YFP 
mice were crossed to K5-CreERT mice and furthermore to LangerinDTR:EGFP mice, 
giving the possibility for inducible activation of the SmoM2 transgene and to also 
deplete LCs at later timepoints.  
In this model the treatment with Imiquimod was adjusted to human treatment 
conditions. SmoM2LangerinDTR mice were treated with Aldara for 5 consecutive 
days followed by 2 days of recovery. This treatment schedule was followed for 2 
weeks – which resembles the treatment duration in the B16F10 melanoma model – 
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to evaluate the efficiency of Imiquimod application in a mouse BCC model. Unlike in 
B16F10 tumor bearing mice, histological analysis did not show reduced growth of 
BCC formations in SmoM2LangerinDTR mice after 2 weeks of Aldara application. 
Human data show that by 2-3 weeks of treatment, Aldara application is accompanied 
by strong inflammation (swelling, redness, encrustation). 4-6 weeks after starting 
treatment with Aldara, a regression of the BCC can be observed. Immune cell 
infiltration into the dermal compartment of SmoM2LangerinDTR mice following 
Imiquimod treatment was observed, showing that Imiquimod exhibits its 
proinflammatory effects also in SmoM2LangerinDTR mice bearing BCC. This is 
manifested by epidermal thickening upon Imiquimod application and immune cell 
infiltration into the dermis. Since histological analysis of BCC bearing 
SmoM2LangerinDTR mice showed that a 2 week treatment is not sufficient to clear 
BCC lesions, Imiquimod treatment will therefore be prolonged to a time span of 6 
weeks in ongoing experiments.  
I found that in SmoM2LangerinDTR mice BCC occurrence is always accompanied by 
strong melanocyte accumulation around BCC foci, as can be seen in H&E 
histological stainings. This goes along with human BCC, which is in 85% of the cases 
accompanied by pigmentation (Altamura, 2009). As Giemsa stainings show, mast cell 
numbers are also increased in BCC affected mouse skin. Total mast cell numbers 
are significantly raised after 2 weeks of BCC progression in untreated mice, whereas 
upon Imiquimod application no furthermore increase in mast cell numbers can be 
detected. In contrast, the B16F10 melanoma model could show that mast cell 
degranulation is significantly enhanced in all Imiquimod treated mice.  
To observe, which role LCs play in BCC growth and whether LCs do have an 
inhibitory effect on mast cell degranulation upon Aldara treatment in the BCC model, 
LC depletion experiments need to be performed with SmoM2LangerinDTR mice.  
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5. Material 
 
 
5.1 Buffers 
Tail DNA preparation – lysis buffer: 50mM TrisHCl pH 8.0, 100mM EDTA, 100mM  
         NaCl, 1% SDS, 0.5mg/ml Proteinase K  
Tail DNA preparation – dissolving buffer: 10mM TrisHCl pH 8.0, 1mM EDTA  
Epidermal single cell suspension - Würzburg buffer: 1% FCS, 5mM EDTA, 20µg/ml  
                 DNaseI 
Red blood cell lysis - ACK lysis buffer:  8.024mg/L NH4Cl, 1.001mg/L KHCO3,  
         3.722mg/L EDTA 
 
 
5.2 Reagents and solutions 
DPBS - # H15-002; PAA Laboratories 
HBSS - # 14175-053; Gibco Invitrogen 
FCS - # A15-043; PAA Laboratories 
DMEM - # E15-810; PAA Laboratories 
Pen/Strep - # P11-010; PAA Laboratories 
L-Glutamin 200mM - # M11004: PAA Laboratories 
Sodiumbicarbonate - # 1.06329.0500; Merck 
Trypsin - # 27250-018; Invitrogen 
Gelatine from porcrine skin, Type A - # G1890-100G; Sigma Aldrich 
DMSO - # 1.09678.0100; Merck 
Perm Wash - # 554723; BD Biosciences 
Tamoxifen – # M77181863; Molecula 
Sunflower seed oil - # S5007-250; Sigma Aldrich 
Ethanol - # 1.00983.2500; Merck 
Aldara - # EU/1/98/080/001; Meda AB 
DT - # 150; List 
Liberase - # 05 401 127 001; Roche 
DNaseI - # DN25; Sigma Aldrich 
EDTA - # 8418.1000; Merck 
Isopropanol - # 1.09634.1011; Merck 
TrisHCl - # 4855.2; Roth 
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SDS - # 4360.2; Roth 
Proteinase K - # 03115879001; Roche 
Taq-Polymerase - # 11 435 094 001; Roche 
Cell culture grade water - # S15-012 PAA Laboratories 
dNTPs - # U1240; Promega 
10x PCR Buffer - # 11 473 100; Roche 
Agarose - # A9539-500G; Sigma Aldrich 
Paraformaldehyde - # 8.18715.1000; Merck 
OCT Tissue Tek - # 4583; Sakura Finetek Europe   
BSA - # A3059-100G; Sigma Aldrich 
Normal goat serum – # ; DAKO 
Ammoniumthiocyanate - # 1.01213.0500; Merck 
Acetone - # 1.00014.1011; Merck 
FluoPrep - # 75521; BioMerieux Sa 
Entellan - # 1.07961.0100; Merck 
Hematoxylin - # HHS32-1L; Sigma Aldrich 
Eosin - # HT110132-1L; Sigma Aldrich 
Giemsa - # 1.09204.0500; Merck 
Acetic acid - # 1.00063.2500; Merck 
NeoClear (Xylol-Substitute) - # 1.09843.5000; Merck 
Paraffin 
ImmEdge Pen - # HH-400; Vector Laboratories 
Hoechst 33342 - #B2261-1G; Sigma Aldrich 
7‘AAD - # 129935; CalBiochem 
Needles – Microlance 3 (# 300700; # 300400; # 300300); BD 
Syringes – # BS-01T; Terumo Europe   
Ketanest - # 400002935; Pfizer  
Rompun - # 79055935; Bayer Health Care 
NaCl - # 1.06404.1000; Merck 
NH4Cl - # 1.101145.1000; Merck 
KHCO3 - # 1.04854.1000; Merck 
MgCl2 - # 2189.1; Roth 
(NH4)2SO4 - # 1.01216.1000 Merck 
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5.3 Antibodies 
CD3e – A488 - # 100321; BioLegend 
CD3e – PE - # 553064; BD Pharmingen 
CD4 – FITC - # 553729; BD Pharmingen 
CD4 – PE - # 553653; BD Pharmingen 
CD3e – PE-Cy7 - # 100320; BioLegend 
CD8a – FITC - # 553031; BD Pharmingen 
CD8a – Horizon - # 560469; BD Pharmingen 
CD11b – Pb - # 101224; BioLegend 
CD11c – FITC - # 553801; BD Pharmingen 
CD11c – APC - # 550261; BD Pharmingen 
CD45 – APC-Cy7 - # 103116; BioLegend 
CD45R (B220) – APC - # 553092; BD Pharmingen 
CD103 – PE - # 121406; BioLegend 
CD115 – PE - # 135506; BioLegend 
CD207 (Langerin) – FITC - # DDX0362; Dendritics 
CD326 (EpCAM) – FITC - # 118210; BioLegend 
F4/80 – Pe-Cy7 - # 123114; BioLegend 
GR-1 – PE - # 553108; BD Pharmingen 
Ly6C – APC - # 560595; BD Pharmingen 
MHC-II – FITC - # 553623; BD Pharmingen 
MHC-II – PE - # 107608; BioLegend 
MHC-II – Pb - # 107620; BioLegend 
mPDCA-1 – FITC - # 120-002-289; MACS Miltenyi Biotec 
NK1.1 – APC - # 17-5941-81; eBioscience 
Vg3 – FITC - # 553229; BD Pharmingen 
CD16/32 - # 101302; BioLegend 
Active caspase-3 - # 557035; BD Pharmingen 
Phospho-Ser10-HistoneH3 - #9701 ; Cell Signaling  
anti-rabbit-A488 - # A11034; Invitrogen 
anti-rabbit-A594 - # A11012; Invitrogen 
anti-rat-A488 - # A11006; Invitrogen 
anti-rat-A594 - # A11007; Invitrogen 
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5.4 Primer  
Langerin-DTR:  
LangEGFP forward – 5’GAA TGA CAG ATC TGG CCT GAG CTC G –3‘ 
LangEGFP reverse – 5’GTA GCT TTT ATA TGG TCA GCC AAG G –3‘   
 
SmoM2:  
HE1 (detects YFP) forward – 5’CTG ACC CTG AAG TTC ATC TGC –3‘ 
HE2 (detects YFP) reverse – 5’GTG CGC TCC TGG ACG TAG – 3‘ 
WT3621 – 5’CGT GAT CTG CAA CTC CAG TC –3‘ 
WT316 – 5’GGA GCG GGA GAA ATG GAT ATG –3‘ 
 
 
5.5 Mice 
Langerin-DTR:EGFP mice were a kind gift from Prof. Dr. Adrien Kissenpfennig. They 
were maintained in C57BL/6 background. Via injection of DT, these mice efficiently 
get depleted of LCs and Langerin+ dDCs 24h after injection.  
Prof. Dr. Fritz Aberger kindly provided Rosa26SmoM2YFP mice, which were 
backcrossed to K5-CreERT C57BL/6 mice, to allow tamoxifen inducible activation of 
the smoothened transgene in the skin. Furthermore, Rosa26SmoM2YFP K5CreERT 
were crossed to LangerinDTR:EGFP mice to generate BCC developing mice that can 
be depleted of LCs.  
 
 
5.6 Equipment 
Epifluorescence and Light Microscope – Nikon Eclipse 80i 
Confocal Fluorescence Microscope - Zeiss 
FACS – BD LSR-II 
Schiebelehre 
 
 
5.7 Software 
Epifluorescence and Light Microscope – Nikon LuciaG 
FACS - BD FACSDiva Software for recording 
FACS – FlowJo for analysis 
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6. Methods 
 
 
6.1 Animal handling and tissue preparation 
All animal experiments were approved the Ethics Committee of the Medical 
University of Vienna. All mice were treated according to institutional guidelines.  
 
 
6.1.1 Tumor models 
 
 
6.1.1.2 B16F10 melanoma growth protocol  
 
 
6.1.1.2.1 Cell culture and melanoma cell injection 
B16F10 melanoma cells were cultured in DMEM supplemented with 10% FCS, 
penicillin/streptomycin, glutamate and sodiumbicarbonate for 2 – 3 passages at 
37°C. During each passage they were washed twice with 1x PBS, trypsinized for 1 
min, washed twice with medium and split into 0.1% gelatine coated cell culture flasks. 
For injection into mice, cells were grown until they reached 60-70% confluence,  
washed twice with 1x PBS, trypsinized for 1 min, washed twice with PBS and finally 
diluted to a concentration of 7.105 cells/ml with 1x PBS. Cells were kept on ice until 
injected 3.5.104 cells/mouse subcutaneously into anesthesized Langerin-DTR:EGFP 
mice.  
 
 
6.1.1.2.2 B16F10 melanoma growth monitoring and treatment 
Tumors appeared 7-10 days after subcutaneous injection and were measured in 
diameter from two sides (A and B) using a mechanical caliper rule. Tumor volume 
was calculated from the excel formula 
 
=MAX(Rohdaten!A:B)*MIN(Rohdaten!A:B)^2*PI()/6 
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Tumors were measured every second day and growth was monitored until tumor size 
was ethically inconsistent. Mice were then sacrificed and parts of the tumor were 
embedded into OCT tissue tek, fixed in 4% paraformaldehyde for further paraffin 
embedding, and FACS analyzed (see 6.1.6).  
Tumor bearing Langerin-DTR:EGFP were subdivided into four groups: untreated, LC-
depleted, Imiquimod-treated and LC-depleted Imiquimod treated. Aldara was applied 
topically to tumor-overlaying skin as well as to tumor-proximate skin. All Imiquimod 
treated mice were separated from non-Imiquimod treated mice to avoid systemic side 
effects among treated and untreated groups by licking the treated area. Imiquimod 
application occurred every second day along with tumor size measurement. LC-
depletion of mice was performed via injection of diphtheria toxin i.p. in a 
concentration of 200ng/mouse every fourth day to ensure consistent depletion of LCs 
during the whole experimental time duration.  
 
 
6.1.1.3 BCC induction and treatment protocol 
Rosa26SmoM2YFP (K5CreERT) Langerin-DTR:EGFP mice were given 30µl of  
tamoxifen (10 mg/ml) daily from P10 – P15, followed by tamoxifen injections once a 
week (concentration depending on weight of mice) until they got sacrificed. By P60-
P80, first BCC lesions were observed. At day 90 mice were subdivided into four 
groups: WT untreated, WT Imiquimod treated, BCC untreated and BCC Imiquimod 
treated mice. At the first day of treatment (day 0), mice were anesthesized and one 
ear was cut off, to be used for frozen and paraffin histology as well as for preparation 
of epidermal ear sheets. Aldara was applied topically on the residing ear and the tail. 
Imiquimod treatment occurred twice for 5 consecutive days, separated by 2 days of 
recovery. At day 102 (experimental day 12), mice were sacrificed and ear, back and 
tail skin were frozen in OCT tissue tek, fixed in 4% paraformaldehyde and processed 
for FACS analysis (see 6.1.5).  
 
 
6.1.2 Tail DNA preparation 
5mm of tail tip were cut off with an ethanol cleaned scissor and added to 500µl of tail 
buffer. Prior to use, tail buffer was supplemented with 0.5mg/ml Proteinase K. Tail 
tubes were incubated over night at 55°C to allow tissue digestion. 200 µl of 6M NaCl 
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were added and tubes were centrifuged for 10 min at 13,000 rpm. Supernatants were 
transferred to a fresh tube and 500 µl of isopropanol were added. After centrifugation 
for 10 min at 13,000 rpm, supernatant was removed and pellet was washed with 70% 
ethanol. Pellets were air-dried after centrifugation for 15 min at 13,000 rpm and 
dissolved in 500 µl of TE buffer, shaking 2-3 h at 37°C. Tail tubes were stored at 4°C.  
 
 
6.1.3 Anesthesia 
Ketanest  10 ml  
Rompun   2 ml 
Aqua dest.  28 ml 
 
 
6.1.4 Melanoma cell injection 
B16F10 melanoma cells were suspended in 1x PBS and kept on ice until injected 
intradermally at a concentration of 3.5.104 cells/mouse into anesthesized Langerin-
DTR:EGFP mice.  
 
 
6.1.5 Preparation of epidermal ear sheets 
Ears were cut off and dorsal half was separated from ventral half. Then they were 
collected dermal-side down on 1x PBS and kept on 4°C over night or processed 
immediately. Ears were transferred onto 0.1% ammoniumthiocyanate solution and 
incubated for 25 min at 37°C. Thereafter, epidermis was peeled off with forceps and 
washed three times with 1x PBS for 5 min each. Epidermal sheets were then fixed in 
4% paraformaldehyde for 30 min at 4°C, washed three times with 1x PBS for 5 min 
each and finally frozen in 2% BSA in PBS. 
 
 
6.1.6 Skin single cell suspension 
Ears and tail were cut off from mice; ears got separated into dorsal and ventral half, 
whereas tail skin was freed from vertebral bodies. Skin parts were cut into small 
pieces (5-10 mm2) and collected in a 50ml Falcon tube containing 2ml of HBSS 
supplemented with 0.15 mg/ml liberase & 0.12 mg/ml DNaseI. Tubes were incubated 
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in the water bath for 1h at 37°C. Afterwards 0,01 mM EDTA were added to stop the 
digestion reaction and skin fragments were pipetted up and down extensively in 
additional 5 ml of Würzburg buffer. The obtained cell suspension was added on a 
Falcon cell strainer positioned on a fresh tube. Another 5ml of Würzburg buffer were 
pipetted onto the cell strainer to increase the cell yield. Cells were centrifuged for 5 
min at 1,260 rpm at 16°C and washed in PBS-FCS (1x PBS containing 8% FCS).  
Cells were counted at the CASY cell counter and resuspended in appropriate 
volumes of PBS-FCS to achieve final concentrations of 1.106 cells/FACS staining.  
 
 
6.1.7 Tumor single cell suspension 
B16F10 melanomas were isolated from LangerinDTR:EGFP mice and freed from 
tumor-overlaying skin. Tumors were cut into small pieces and collected in 2ml 
eppendorf tubes containing 1,2 ml of PBS supplemented with liberase [10 µg/ml]. 
Tubes were incubated in a thermo shaker, shaking at 900 rpm for 1h at 37°C. The 
solution was homogenized by pipetting up and down and transferred to a cell strainer 
positioned on a 50ml falcon tube. 10 ml of PBS-FCS were added onto the cell 
strainer to increase the cell yield and to stop the digest. Cells were centrifuged for 5 
min at 1,260 rpm at 16°C and dissolved in 3ml of ACK lysis buffer to remove red 
blood cells. Immediately after homogenization, 3 ml of PBS-FCS were added to stop 
the reaction. Cells were centrifuged for 10 min at 1,260 rpm at 16°C and washed in 
PBS-FCS.  After centrifugation for 5 min at 1,260 rpm at 16°C, cells were counted on 
a CASY cell counter and resuspended in appropriate volumes of PBS-FCS to 
achieve final concentrations of 1.106 cells/FACS staining.  
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6.2. Immunology 
 
 
6.2.1 FACS analysis 
 
 
6.2.1.1 Extracellular staining of cells 
Single cell suspensions from whole-skin and B16F10 tumors were transferred to 
Micronic FACS tubes and incubated with Fc-Block for 5 min on ice. 5µl of each 
antibody mixture for extracellular molecules were propounded into the staining FACS 
tubes and 50µl of each cell suspension were added (note: not only whole antibody 
mixtures were used, but also single staining of every stained color occurred for 
proper emission compensation during the FACS recording). After vortexing, cells 
were incubated for 25 min in the dark on 4°C. Cells were washed twice with 500 µl 
PBS-FCS, centrifuged for 5 min at 1,260 rpm at 16 °C, and vortexed after every 
washing step. For analysis, they were diluted in a volume of 50µl.  
 
 
6.2.1.2 Intracellular staining of cells 
After extracellular staining of cells, the cells were fixed in 200 µl 2% 
paraformaldehyde at least for 30 min. Afterwards, they were washed twice in 500 µl 
PBS-FCS, then washed twice in 500 µl perm wash, followed by incubation in 100 µl 
perm wash for 15 min. Cells were then washed once more in 500 µl perm wash. 5 µl 
of antibody mixture for intracellular antibodies were added, the whole mix got 
vortexed and incubated for 25 min at 4°C in the dark. After another two washing 
steps with 500µl PBS-FCS, cells were diluted in a final volume of 50 µl. 
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6.3. Microscopy  
 
 
6.3.1. Immunofluorescence 
 
 
6.3.1.1 Cryosections 
5µm tissue sections were performed in a diameter of  at a HM500OM Microm 
Cryostat. Until further use, tissue samples were stored at -80°C, whilst frozen 
sections were stored at -20°C. For immunofluorescent stainings, cryosections were 
temperature equilibrated and air-dried for 10 min at room temperature. Following 
fixation in ice cold acetone for 20 min, samples were air-dried again for 10 min and 
then washed in 1x PBS trice for 5 min each. The area around the sections was dried 
carefully with a paper towel and a circle was drawn around every section with a TAP-
Pen. Slides were positioned in a humid chamber and each section was incubated in 
100µl blocking solution (10% goat serum in 2% BSA-PBS) for 30 min at room 
temperature. After removing the blocking solution, 100 µl of antibody mixtures 
(antibodies diluted in 2% BSA-PBS) were pipetted onto each section and the slides 
were incubated at 4°C over night. Afterwards, sections were washed three times 5 
min each in 1x PBS and then incubated in 100 µl 1 mg/ml Hoechst for 20 min. After 
washing 3 times for 5 min each in 1x PBS, sections were mounted in FluoPrep 
aquaeous mounting medium and stored in the dark at 4°C until further usage for 
microscopy.  
 
 
6.3.1.2. Ear sheets 
After preparation of epidermal ear sheets (see 6.1.4 Epidermis-dermis separation), a 
part of every frozen epidermal sheet was cut off with a scalpel knife and transferred 
into a chamber of a 48 well plate, each chamber filled with 100 µl blocking solution 
(10% goat serum in 2% BSA-PBS). After incubation for 30 min at room temperature, 
blocking solution was removed with a pipette and 100µl of antibody mixture 
(antibodies diluted in 2% BSA-PBS) were added. Incubation occurred at 4°C in the 
dark over night. Sheets were then washed for three times 5 min each and incubated 
for 20 min with 100 µl Hoechst at room temperature. After washing twice for 5 min 
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each, sheets were transferred to glass slides and spread with forceps under a 
binocular light microscope. Finally, ear sheets were mounted in FluoPrep and kept at 
4°C in the dark until further use for microscopy.  
 
 
6.3.2. Light microscopy 
 
 
6.3.2.1. H&E 
Paraffin embedded tissue samples were cut in a diameter of 5 µm at a microtome 
and applied to DAKO microcapillar 70µm glass slides. They were stored at room 
temperature until usage for histological staining. After minimum 30 min incubation of 
glass slides at 55°C, the sections were deparaffinized in NeoClear for 2x 1 min, 
followed by rehydration: 2x 100% ethanol, 2x 70% ethanol, 2x distilled water for 1 
min each. Slides were incubated in freshly filtrated Hematoxylin for 5 min and 
differentiated in flowing tap water for 5 min and incubation in HCl-water for 5 sec. 
After incubation in distilled water for 1 min, slides were incubated in Eosin for 45 sec, 
followed by a dehydration series: 2x 96% ethanol, 2x 100% ethanol, 2x NeoClear for 
1 min each. Sections were mounted in the non-aquaeous mounting medium Entellan 
and stored at room temperature until further use.   
 
 
6.3.2.2. Giemsa 
Paraffin embedded tissue samples were cut in a diameter of 5 µm at a microtome 
and applied to DAKO microcapillar 70µm glass slides. They were stored at room 
temperature until usage for histological staining. After minimum 30 min incubation of 
glass slides at 55°C, the sections were deparaffinized in NeoClear for 2x 1 min, 
followed by rehydration: 2x 100% ethanol, 2x 70% ethanol, 2x distilled water for 1 
min each. Sections were incubated in freshly prepared Giemsa solution (Giemsa 
stock solution diluted 1:3 in distilled water) for 18 min. For differentiation, sections 
were first transferred to 0.1% acetic acid for 2 min and then incubated in 96% ethanol 
for 1 min. After dehydration in 2x 96% ethanol, 2x 100% ethanol and 2x NeoClear for 
1 min each, sections were mounted in the non-aquaeous mounting medium Entellan 
and stored at room temperature until further use.   
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6.4 Statistical analysis 
Mice from Langerin-DTR:EGFP B160F10 melanoma model were grouped into 
untreated, LC-depleted, Imiquimod treated and LC-depleted Imiquimod treated mice, 
whereas Rosa26SmoM2YFP K5CreERT Langerin-DTR:EGFP mice were grouped into 
WT untreated, WT Imiquimod treated, BCC untreated and BCC Imiquimod treated 
mice.  Variance of LC density, mast cell frequency, epidermal thickness, and immune 
cell infiltration into B16 melanoma tumors, BCC lesions and skin within the groups 
was measured. Statistical analysis was performed using the two-sided Student´s t-
test.  
p < 0,05 (*) 
p < 0,01 (**) 
p < 0,001 (***) 
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8.2 List of Abbreviations 
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CD – cluster of differentiation 
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DHH – desert hedgehog 
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DTR – diphtheria toxin receptor 
EDTA - ethylenediaminetetraacetic acid 
EGFP – enhanced green fluorescent protein 
EGFR – epithelial growth factor receptor 
EpCAM – epithelial cell adhesion molecule 
ER – estrogen receptor 
ERT – estrogen receptor tamoxifen complex 
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GLI – glioblastoma 
H&E – hematoxylin & eosin 
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Hh – Hedgehog 
IFN – interferon 
IHH – Indian hedgehog 
IL – Interleukin 
IMQ – Imiquimod 
IRAK – interleukin-1-receptor-associated kinase 
K5 – keratin5 
LC – Langerhans cell 
LN – lymph node 
MAPK – mitogen-activated protein kinase 
mDC – myeloid DC 
MHC – major histocompatibility complex 
mPDCA – murine plasmacytoid dendritic cell antigen 
MyD88 – myeloid differentiation primary response gene 88 
NaCl – sodium chloride 
Neo - neomycin 
NK – natural killer 
OGFR – opioid growth factor receptor 
P – postnatal day 
PBS – phosphate buffered saline 
pDC – plasmacytoid DC 
PDGFR – platelet derived growth factor receptor 
PI3K – phosphoinositol-3-kinase 
PTCH – patched 
RGP – radial growth phase 
RNA – ribonucleic acid 
SCC – squamous cell carcinoma 
sDLN – skin draining lymph node 
SDS - sodium dodecylsulfate 
SHH – sonic hedgehog 
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SMO – smoothened 
SMO DTR-KI/+ - SmoM2:YFPfl/fl K5CreERT/+ LangerinDTR:EGFP/+ 
smoM2 – constitutively active isoform of smo 
SP – single positive 
ss – single stranded 
SUFU – suppressor of fused 
T - thymidine 
TCR – T cell receptor 
TE – Tris-EDTA 
TGF – transforming growth factor 
TH1 – T helper 1 
TLR – toll-like receptor 
TNF – tumor necrosis factor 
TRAF – TNF receptor associated factor 
UV – ultraviolet 
UVR – ultraviolet radiation 
VGP – vertical growth phase 
WT – wild type 
YFP – yellow fluorescent protein 
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(1) Molecular biology  
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at the University of Vienna, Austria 
 
 
Fellowships:  
2005-2010  Fellowship of Prof. Dr. Zerweck-/Cassella-Stiftung, Frankfurt am Main, 
Germany 
 
 
Employments:  
08 2008 Volunteer at Momentum Pharma, Hamburg, Germany  
07/08 2006 Organical chemistry laboratory at AllessaChemie, Frankfurt am Main, 
Germany 
07/08 2004 Analytical pharmacy laboratory at AllessaChemie, Frankfurt am Main, 
Germany 
08 2003 Analytical pharmacy laboratory at AllessaChemie, Frankfurt am Main, 
Germany 
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Since 2008 Member of Rotaract Wien Innere Stadt, Vienna, Austria 
Since 2006 Member of Molecular Biological Society, Vienna, Austria 
Since 2002  Member of scuba diving club Bad Orb, Germany 
 
